Targeted Genetics gets patent to protect composition of AAV vectors

By E. Janene Geiss

Philadelphia, Sept. 14 - Targeted Genetics Corp. announced Thursday the issuance of a new patent that further strengthens the company's leadership in developing adeno-associated virus (AAV)-based therapies.

U.S. Patent No. 7,105,345, titled "Adeno-Associated Virus Serotype 1 Nucleic Acid Sequences, Vectors And Host Cells Containing Same," covers compositions of AAV vectors that encode capsid proteins derived from AAV serotype 1 (AAV1) and host cells into which such vectors are introduced, the Seattle biopharmaceutical company said in a news release.

The patent is a continuation of U.S. Patent No. 6,759,237 that provides additional protection around recombinant AAV vectors that the company is using in several product development programs.

The patent was issued to the University of Pennsylvania and is exclusively licensed to Targeted Genetics. It covers both AAV1 serotype and AAV1 pseudotyped vectors. Vectors of one serotype that are engineered to express capsid proteins of a different serotype are said to be "pseudotyped."

The company and its partners are evaluating AAV1 pseudotyped vectors in an HIV/AIDS vaccine and congestive heart failure and Huntington's disease product development programs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.